Estrogen and Atherosclerosis

Journal of Investigative Medicine

Volumn 46, Issue 8, 1998, Pages 381-386

  Mosca, Lori ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ANIMAL; ARTERIOSCLEROSIS; ESTROGEN THERAPY; FEMALE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

ANIMALS; ARTERIOSCLEROSIS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; RISK FACTORS;

EID: 0032184897     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women. A Statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2468-82.
2. American Heart Association. 1998 Heart and stroke facts: statistical update. Dallas: American Heart Association, 1998.
3. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998;351:1425-27.
4. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? Circulation 1997;95:252-64.
5. Lobo RA. Hormones, hormone replacement therapy, and heart disease. In: Douglas PA, ed. Cardiovascular health and disease in women. Philadelphia: WB Saunders Company; 1993:153-73.
6. Hahn R, Eaker E, Rolka H. Reliability of reported age at menopause. Am J Epidemiol 1997;146(9):771-5.
7. Lidnquist O. Intraindividual changes of blood pressure, serum lipids and body weight in relation to menstrual status: results from a prospective population study of women in Goteborg, Sweden. Prev Med 1982;11:162-72.
8. Kuller LH, Meilahn EN, Cauley JA, Gutai JP, Matthews KA. Epidemiologic studies of menopause: lessons from the healthy women study. Exp Gerontol 1994;29:337-42.
9. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-6.
10. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
11. Guetta V, Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996;93:1928-37.
12. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? Circulation 1995;92:508.
13. Anderson H.V. Estrogen therapy, atherosclerosis, and clinical cardiovascular events. Circulation. 1996;94:1809-11.
14. Selzeman CH, Whitehall TA, Shames BD, Pulido ES, Cain BC, Harken AH. The biology of estrogen-mediated repair of cardiovascular injury. Ann Thoracic Surg 1998;65:868-74.
15. Sacks FM, Campos H, Judge H, Walsh BW. Estrogen treatment and human lipoprotein metabolism. In: Forte TM, ed. Hormonal, metabolic, and cellular influences on cardiovascular disease in women. Armonk, NY: Futura Publishing Company, Inc. 1997:229-46.
16. Banka C. Antioxidant properties of estrogen. Selective protection of high-density lipoprotein. In: Forte TM, ed. Hormonal, metabolic, and cellular influences on cardiovascular disease in women. Armonk, NY: Futura Publishing Company, Inc. 1993fg:193-214.
17. Cannon RO III. Antioxidant effects of estrogen. Administered to postmenopausal women. In: Forte TM, ed. Hormonal, metabolic, and cellular influences on cardiovascular disease in women. Armonk, NY: Futura Publishing Company, Inc.;1993:215-28.
18. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, Schrott H, Bush TL. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998;97:979-86.
19. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation 1987;75:1102-09.
20. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in relation of arterial smooth muscle by acetylcholine. Nature 1980;228:373-6.
21. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-2551.
22. Vogel RA, Corretti MC, Estrogens, progestins, and heart disease. Can endothelial function divine the benefit? Circulation 1998;97:1223-6.
23. Williams JK, Adams MR, Klopfenstein S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:1680-7.
24. Topol EJ, Califf RM, Van dedWerf F, Simoons M, Hampton J, Lee KL, White H, Simes J, Armstrong P. Perspectives of large-scale cardiovascular clinical trials for the new millennium. Circulation 1997;95:1072-82.
25. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-5.
26. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone replacement therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
27. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991;20:47-63.
28. Rossow JE, Finnegan LP, Harlan WR, Pinn VW, Clifford C, McGowan JA. The evolution of the Women's Health Initiative: perspectives from NIH. J Am Med Women Assoc 1995;50:50-5.
29. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-61.
30. Adams MR, Register TC, Golden DL, Wanger JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vase Biol 1997;17(1):217-21.
31. Miyagawa K, Rosch J, Stanczyk E, Hermsmeyer K. Med Roxy progesterone interfers with ovarian steroid protection against coronary vasospasm. Nat Med 1997;3(3):273-4.
32. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998;97:1234-8.
33. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
34. Barren-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annual Review of Public Health 1998;19:55-72.
35. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
36. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997;127(7):501-8.
37. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-53.
38. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-12.
39. Petitti DB. Hormone replacement therapy and heart disease prevention. JAMA 1998;280:650-2.